Atossa Genetics is a clinical-stage pharmaceutical company focused on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. Our leading program uses our patented intraductal microcatheters that deliver pharmaceuticals through the breast milk ducts. We initiated a Phase 2 clinical study in March 2016 using our microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ, or DCIS, and breast cancer. This study is being conducted by Columbia University Medical Center Breast Cancer Programs (New York). Oral endoxifen is our second development program. Endoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer patients to prevent recurrence as well as new breast cancer. We are developing oral endoxifen for breast cancer patients who are refractory to tamoxifen which means they get little or no benefit from the drug. It is estimated that over one million people take tamoxifen annually in the United States and that up to 50% of those patients are refractory for any number of reasons, including low levels of a liver enzyme. We expect to initiate a Phase 2 clinical study for this drug in 2017. In late 2015, we completed a strategic assessment and restructuring aimed at focusing our resources on our pharmaceutical programs. On December 16, 2015 we sold approximately 81% of the capital stock of the The National Reference Laboratory for Breast Health Inc. (the “NRLBH”), which had historically provided various diagnostic tests including for specimens collected with our breast aspirator devices.

IR Nav

Tear Sheet IR Contacts Subscribe to News Alerts RSS Feed

Company Profile

2345 Eastlake Ave E, Suite 201
Seattle, WA 98102





Intraday stock chart for ATOS


Steven C. Quay, M.D., Ph.D.

Chairman of the Board and Chief Executive Officer

Kyle Guse, Esq., CPA

Chief Financial Officer, General Counsel and Secretary

Janet Rose Rea, M.S.P.H.

Vice President, Regulatory Affairs and Quality

View Management Team

Past Six Months

6 month stock chart for ATOS

Recent News & Filings

Atossa Genetics Corporate Presentation September 2016 10-K - Dec 31, 2016 10-Q - Mar 31, 2017

Investor Relations

Scott Gordon
President Core IR
377 Oak Street
Garden City, NY 11530
T: 516-222-2560

Transfer Agent

VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516
Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179


600 University Street
Suite 2528
Seattle, WA 98101-1176

Corporate Counsel

Gibson Dunn
555 Mission Street, Suite 3000
San Francisco, CA 94105-0921

Intellectual Property:
Wilson, Sonsini, Goodrich & Rosati LLP
1301 Avenue of the Americas
New York, NY 10019

Subscribe to IR news and filing alerts

You can opt out at any time. We do not share or sell your info.